Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

The Tokyo Lion SLGC009: the look and feel of a lion The Grand Seiko Sport Collection Tokyo Lion Tentagraph SLGC009 (€17,500) also uses the lovely caliber 9SC5, but the watch’s Brilliant Hard Titanium ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Plants don't just grow, they build. From towering trees to delicate flowers, complex plant shapes are sculpted with ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. But don’t worry—you’re definitely not alone. We’re here to share all the ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...